Brands
Milton and Kala Ghoda Unite for artful sustainability revolution
Mumbai: Milton, a one of the leading in-home essentials announced its partnership with the Kala Ghoda Art Festival, a celebration of art and culture held annually in Mumbai. This marks the first-ever collaboration between Milton and the prestigious festival, reinforcing the brand’s commitment to sustainability and cultural enrichment.
The Kala Ghoda Art Festival, organised by the Kala Ghoda Association, has been a cornerstone of Mumbai’s cultural scene since its inception in 1999. The nine-day extravaganza attracts art enthusiasts from across the nation and the globe, showcasing diverse sections such as dance, music, theatre, films, food, literature, heritage, architecture, stand-up comedy, children’s activities, and Visual art, making it a truly unique experience.
As Associate Sponsors of the event, Milton to play a vital role in supporting and propagating the message of environmental stewardship throughout the festival. The brand has curated a range of engaging activities aimed at cultivating a sense of environmental responsibility among festival-goers.
Key Initiatives by Milton at Kala Ghoda Art Festival:
Pledge gate at Rampart road: An interactive installation featuring Milton’s colored steel bottles, allowing participants to scan a QR code and take a pledge to reduce or reuse single-use plastics.
Plastic to steel installation at cross-maidan: A compelling art installation encouraging attendees to abandon plastic in favour of sustainable steel alternatives.
Gaming engagement kiosk: A fun-filled kiosk featuring engaging games like ring-throw, aimed at educating and entertaining participants about sustainability.
Food workshops with Milton procook cooking range: Renowned chefs will lead engaging food workshops, shedding light on the significance of utilizing food-grade and sustainable materials in cookware for enhancing the culinary experience and promoting eco-friendly practices.
Instagram booth – ProCook avatar: Created an Instagram booth that captures the essence of culinary expertise. The installation features an Instagram feed post visual of a chef effortlessly tossing veggies in a pan, showcasing culinary skills. It includes a cutout for the face, allowing visitors to stand behind it and click pictures, creating a Pro Cook avatar experience. Festival-goers can immerse themselves in the world of professional cooking, adding a fun and interactive element to the overall experience.
In addition there will be “Art Competition for Children” providing a creative platform, with the winning drawing featured on a limited edition Milton bottle. Moreover, Milton will be offering “Limited Edition Kala Ghoda Bottles” exclusively for sale on its website, allowing attendees to take home a piece of the festival while promoting sustainability.
Speaking on the collaboration, Hamilton CSR head Manisha Vaghani said, “As Milton joins hands with the Kala Ghoda Art Festival, we are excited to contribute to the vibrant cultural tapestry of Mumbai and champion the cause of sustainability. These initiatives underscore our dedication to making a positive impact on both cultural experiences and environmental consciousness.”
Kala Ghoda Association, chairperson Brinda Miller added, “We are excited to embrace Milton’s steadfast commitment to elevating the festival experience and leading the way in championing sustainability. This strategic partnership introduces a fresh and dynamic perspective to our celebration of art and culture. We are confident that this collaboration will not only enhance the overall attendee experience but also serve as an inspiration for a broader audience to wholeheartedly embrace the essential intersection of art and sustainability.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
